Skip to content

Study · Observational study · n = 4,059 · 2024

3 results

Impact of baseline FIB-4 score on efpeglenatide benefits on cardiovascular outcomes in people with type 2 diabetes: a participant-level exploratory analysis of the AMPLITUDE-O trial.

Del Prato S, Li Z, Ramasundarahettige C, Branch KRH, Lam CSP, Lopes RD, Pratley R, Rosenstock J, Sattar N, Gerstein HC

Cardiovascular diabetology28 Sept 2024Cited by 1 (Europe PMC)

PMID39342203 (opens in a new tab)PMCIDPMC11439209 (opens in a new tab)DOI10.1186/s12933-024-02432-7 (opens in a new tab)PepBankPUB-39342203
Read at sourcePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanObservational studyEfficacy outcome

    In people with diabetes, efpeglenatide's MACE effect did not vary across FIB-4 tertiles; all interaction p values were ≥0.64.

    In plain wordsIn people with diabetes, efpeglenatide's MACE effect did not vary across liver fibrosis score categories.

    Peptide
    Efpeglenatide
    Outcome
    No significant changeMACE effect modification by FIB-4
    Study

    n = 4,059

    Comparator
    Baseline FIB-4 tertiles
    Analysis
    Exploratory
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    Dose not stated

    Measurements

    Interaction p value
    ≥ 0.64
    efpeglenatide by FIB-4 tertile, MACE

    Source sentences

    Summary
    Efpeglenatide's effect on all MACE outcomes did not vary across FIB-4 tertiles (all interaction p values ≥ 0.64).
    2 context sentences
    Summary · context
    AMPLITUDE-O trial data were used to estimate the relationship of FIB-4 score categories to the hazard of MACE, expanded MACE, and MACE or death.
    Summary · context
    Interactions on these outcomes between baseline FIB-4 score, and between FIB-4 score and efpeglenatide were also assessed.
  2. 02HumanObservational studyEfficacy outcome

    In people with diabetes, efpeglenatide's expanded MACE effect did not vary across FIB-4 tertiles.

    In plain wordsIn people with diabetes, efpeglenatide's expanded cardiovascular composite effect did not vary across liver fibrosis score categories.

    Peptide
    Efpeglenatide
    Outcome
    No significant changeExpanded MACE effect modification by FIB-4
    Study

    n = 4,059

    Comparator
    Baseline FIB-4 tertiles
    Analysis
    Exploratory
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    Dose not stated

    Measurements

    Interaction p value
    ≥ 0.64
    efpeglenatide by FIB-4 tertile, expanded MACE

    Source sentences

    Summary
    Efpeglenatide's effect on all MACE outcomes did not vary across FIB-4 tertiles (all interaction p values ≥ 0.64).
    2 context sentences
    Summary · context
    AMPLITUDE-O trial data were used to estimate the relationship of FIB-4 score categories to the hazard of MACE, expanded MACE, and MACE or death.
    Summary · context
    Interactions on these outcomes between baseline FIB-4 score, and between FIB-4 score and efpeglenatide were also assessed.
  3. 03HumanObservational studyEfficacy outcome

    In people with diabetes, efpeglenatide's effect on MACE or death did not vary across FIB-4 tertiles.

    In plain wordsIn people with diabetes, efpeglenatide's effect on cardiovascular events or death did not vary across liver fibrosis score categories.

    Peptide
    Efpeglenatide
    Outcome
    No significant changeMACE or death effect modification by FIB-4
    Study

    n = 4,059

    Comparator
    Baseline FIB-4 tertiles
    Analysis
    Exploratory
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    Dose not stated

    Measurements

    Interaction p value
    ≥ 0.64
    efpeglenatide by FIB-4 tertile, MACE or death

    Source sentences

    Summary
    Efpeglenatide's effect on all MACE outcomes did not vary across FIB-4 tertiles (all interaction p values ≥ 0.64).
    2 context sentences
    Summary · context
    AMPLITUDE-O trial data were used to estimate the relationship of FIB-4 score categories to the hazard of MACE, expanded MACE, and MACE or death.
    Summary · context
    Interactions on these outcomes between baseline FIB-4 score, and between FIB-4 score and efpeglenatide were also assessed.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    27 Oct 2026, 18:20 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:32 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.